ורידי ארנב מודל האינטרפוזיציה מחקה ניתוח מחדש באמצעות שתלי וריד כדי להעריך את היפרפלזיה באמצעות לחץ דם עורקי

Executive Industry Relevance

This model enables preclinical evaluation of therapeutic strategies targeting venous intimal hyperplasia, a key failure mode in vascular graft revascularization. By replicating arterial pressure exposure in a surgically accessible venous interposition system, it supports mechanistic de-risking of anti-proliferative interventions before costly large-animal or clinical testing. The platform enhances predictive confidence in target validation for vascular smooth muscle phenotype modulation, directly informing go/no-go decisions in cardiovascular therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses targeting vascular smooth muscle cell phenotype switching from proliferative to contractile state.
• Operational Value: Provides a reproducible in vivo system to validate target engagement and functional impact of molecular interventions like miR-145 delivery.

Screening & Assay Development

• Scientific Value: Generates quantifiable histopathological endpoints (intimal thickness, Ki-67 positivity) for dose-response assessment of candidate therapeutics.
• Operational Value: Supports standardization of venous graft preparation and arterial coupling for consistent phenotypic readouts across studies.

Translational & Preclinical Research

• Scientific Value: Bridges in vitro findings (e.g., miR-145 effects on VSMCs) to physiologically relevant arterial pressure conditions in vivo.
• Operational Value: Facilitates longitudinal monitoring of graft patency and hyperplasia progression, enabling longitudinal efficacy studies.

Pipeline & Workflow Integration

The model fits within the cardiovascular discovery continuum, supporting target validation after in vitro screening and prior to preclinical efficacy testing in larger models or clinical translation.

• Discovery Biology: Tests mechanistic hypotheses about vascular remodeling pathways under pathophysiological mechanical stress.
• Screening: Delivers quantitative histological and immunohistochemical outputs to rank-order therapeutic candidates.
• Analytics: Enables morphometric and proliferative index analysis (e.g., intimal hyperplasia area, Ki-67+) to compare treatment effects.
• Translational Research: Provides disease-relevant venous graft environment to assess continuity of mechanism from cell culture to tissue-level outcome.
• Enterprise Reuse: Establishes a standardized surgical platform adaptable to multiple therapeutic modalities ( nucleic acids, drugs, biologics) for vascular graft improvement.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity in vascular graft failure by isolating intimal hyperplasia as a pressure-dependent process.
• Operational Value: Offers a cost-effective, reproducible model with limited invasiveness, supporting longitudinal studies and reduced animal use.
• Strategic Value: Improves go/no-go criteria by predicting clinical graft failure risk based on hyperplasia attenuation efficacy.
• Portfolio Impact: Enables risk-adjusted prioritization of vascular therapeutic candidates targeting smooth muscle phenotype modulation.

Implementation Considerations

• Requires expertise in microvascular surgical techniques and venous/arterial anastomosis in small mammals.
• Dependent on access to surgical equipment (microsurgical instruments, sutures, balloon catheters, heparin) and postoperative monitoring facilities.
• Necessitates standardized protocols for venous harvest, intimal denusion, and arterial coupling to ensure model reproducibility.
• Adaptation to larger animal models may require scaling of vessel size, suture gauge, and anticoagulant dosing while preserving arterial pressure exposure.
• Outcome assessment depends on histological processing and immunohistochemical staining capabilities for endpoints like intimal thickness and Ki-67.

Biopharma FAQs